

Erratum

In the article by Igawa et al., entitled 'Impact of PD-L1 expression in patients with surgically resected non-small-cell lung cancer' [Oncology 2017;92:283–290, DOI: 10.1159/000458412], the VENTANA PD-L1 (SP263) assay is incorrectly described as a polyclonal antibody. As misunderstanding of the type of antibody could lead to inappropriate interpretation of an assay that may be used for a clinical decision, the authors feel it is important that the correct antibody type be described and state that the VENTANA PD-L1 (SP263) assay contains a rabbit monoclonal primary antibody.